SVB Leerink Initiates Coverage on Alpine Immune Sciences (NASDAQ:ALPN)

SVB Leerink started coverage on shares of Alpine Immune Sciences (NASDAQ:ALPNGet Rating) in a report released on Monday, Marketbeat.com reports. The firm issued an outperform rating and a $15.00 target price on the biotechnology company’s stock. SVB Leerink also issued estimates for Alpine Immune Sciences’ Q4 2022 earnings at ($0.34) EPS, FY2022 earnings at ($1.58) EPS, FY2023 earnings at ($1.31) EPS, FY2024 earnings at ($2.49) EPS, FY2025 earnings at ($2.99) EPS and FY2026 earnings at ($3.11) EPS.

Several other research analysts have also recently issued reports on ALPN. Oppenheimer decreased their price objective on shares of Alpine Immune Sciences from $17.00 to $14.00 and set an outperform rating for the company in a report on Monday, October 24th. Wedbush increased their target price on shares of Alpine Immune Sciences to $25.00 in a research report on Thursday, September 15th. Finally, HC Wainwright cut their target price on shares of Alpine Immune Sciences from $21.00 to $8.00 in a research report on Monday, October 24th.

Alpine Immune Sciences Trading Down 3.7 %

NASDAQ ALPN opened at $6.27 on Monday. The company has a 50-day moving average price of $6.52 and a two-hundred day moving average price of $7.80. The stock has a market cap of $190.61 million, a price-to-earnings ratio of -3.50 and a beta of 1.39. Alpine Immune Sciences has a 52 week low of $4.82 and a 52 week high of $14.40.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of ALPN. Paradigm Biocapital Advisors LP bought a new stake in shares of Alpine Immune Sciences in the first quarter worth $3,016,000. Connor Clark & Lunn Investment Management Ltd. lifted its holdings in shares of Alpine Immune Sciences by 48.8% in the first quarter. Connor Clark & Lunn Investment Management Ltd. now owns 28,316 shares of the biotechnology company’s stock worth $254,000 after acquiring an additional 9,290 shares during the last quarter. Decheng Capital Management III Cayman LLC bought a new position in shares of Alpine Immune Sciences in the first quarter worth about $42,233,000. Jump Financial LLC bought a new position in shares of Alpine Immune Sciences in the third quarter worth about $72,000. Finally, Monashee Investment Management LLC bought a new position in Alpine Immune Sciences in the 3rd quarter valued at approximately $720,000. Institutional investors and hedge funds own 79.01% of the company’s stock.

Alpine Immune Sciences Company Profile

(Get Rating)

Alpine Immune Sciences, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for the treatment of B cell-mediated inflammatory and autoimmune diseases.

See Also

Receive News & Ratings for Alpine Immune Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpine Immune Sciences and related companies with MarketBeat.com's FREE daily email newsletter.